Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population

Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin.

Aim: To reveal the clinical characteristics and metabolic predictors of better hypoglycemic response to evogliptin. Matherials and methods: We have conducted a retrospective study, based on the data of a randomized clinical trial comparing effectiveness and safety of evogliptin and sitagliptin in Russian and Korean subpopulations. We provide univariate linear regression models for separate subpopulations and a multivariate stepwise regression model for the combined subpopulation. HbA1c change after 24 weeks of evogliptin treatment was a primary endpoint and a dependent variable in the analysis.

Results: The decrease of HbA1c after 24 weeks of treatment with evogliptin in Russian subpopulation negatively correlates with triglycerides/HDL level (p = 0,046). In South Korean subpopulation it correlates positively with HbA1c level at baseline (p < 0,0001). In order to increase the statistical power of the analysis the data of both populations were combined. According to the combined data, the decrease of HbA1c after 24 weeks of treatment with evogliptin positively correlates with HbA1c level at baseline (p<0.0001) and log(HOMA-B) (p=0.0042), and it negatively correlates with log(triglycerides/HDL) (p=0.0057), blood phosphorous concentration (p=0.014) and statin treatment (p=0.044). No correlation of HbA1c change at week 24 was observed with body mass index, diabetes duration and blood C-peptide concentration. Patients able to achieve HbA1c<7,0 % had higher HOMA-B (53.22 ± 36.95 и 39.67 ± 24.74, respectively, р=0.033) and were tend to have higher HDL concentration (1.36 ± 0.28 и 1.26 ± 0.26 mmol/l, respectively, р=0.076) and lower triglycerides to HDL ratio (0.87 ± 0.70 и 1.48 ± 0.95, respectively, р=0.079).

Conclusion: A patient, who benefits more when treated with evogliptin, has higher HOMA-B, lower triglycerides to HDL ratio and phosphorous concentration in the 1-2 quartiles of the normal range. Triglycerides to HDL ratio is, probably, a specific effectiveness predictor for Russian, but not for Korean subpopulation. These data prove the difference in effectiveness prediction for different drugs of DPP-4 inhibitors group and reveal the need of further investigation.

diabetes mellitus, personalized medicine, DPP-4 inhibitors, efficacy prediction, evogliptin

1. Шляхто Е.В., Конради А.О. Основные направления и перспективы трансляционных исследований в кардиологии // Вестник Росздравнадзора. — 2015. — №5. — С. 33-37. [Shlyakhto EV, Konradi AO. Key areas and prospects for translational research in cardiology. Vestnik Roszdravnadzora. 2015;(5):33-37 (In Russ.)]

2. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: The promise of personalized medicine. AAPS PharmSci. 2000;2(1):29-41. doi: 10.1208/ps020104

3. Committee on A Framework for Developing a New Taxonomy of Disease, Board on Life Sciences, Division on Earth and Life Studies. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington: National Academy of Sciences; 2011.

4. Tan X, Hu J. Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2016;17(9):1285-1293. doi: 10.1080/14656566.2016.1183645

5. Esposito K, Chiodini P, Maiorino MI, et al. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients. BMJ Open. 2015;5(2):e005892. doi: 10.1136/bmjopen-2014-005892

6. Yagi S, Aihara K, Akaike M, et al. Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2015;39(4):342-347. doi: 10.4093/dmj.2015.39.4.342

7. Mamza J, Mehta R, Donnelly R, Idris I. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database. Diabetes Technol Ther. 2016;18(2):85-92. doi: 10.1089/dia.2015.0052

8. Monami M, Cremasco F, Lamanna C, et al. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362-372. doi: 10.1002/dmrr.1184

9. Kim YG, Hahn S, Oh TJ, et al. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia. 2013;56(4):696-708. doi: 10.1007/s00125-012-2827-3

10. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444(7121):840-846. doi: 10.1038/nature05482

11. Jensen CC, Cnop M, Hull RL, et al. -Cell Function Is a Major Contributor to Oral Glucose Tolerance in High-Risk Relatives of Four Ethnic Groups in the U.S. Diabetes. 2002;51(7):2170-2178. doi: 10.2337/diabetes.51.7.2170

12. Jamaluddin JL, Huri HZ, Vethakkan SR. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics. 2016;17(8):867-881. doi: 10.2217/pgs-2016-0010

13. Zhou K, Pedersen HK, Dawed AY, Pearson ER. Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nat Rev Endocrinol. 2016;12(6):337-346. doi: 10.1038/nrendo.2016.51

14. Tkac I, Gotthardova I. Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers. Pharmacogenomics. 2016;17(7):795-804. doi: 10.2217/pgs-2016-0011

15. Zimdahl H, Ittrich C, Graefe-Mody U, et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia. 2014;57(9):1869-1875. doi: 10.1007/s00125-014-3276-y

16. Oh TJ, Jung HS, Bae JH, et al. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. J Korean Med Sci. 2013;28(6):881-887. doi: 10.3346/jkms.2013.28.6.881

17. Kim HM, Lim JS, Lee BW, et al. Optimal candidates for the switch from glimepiride to sitagliptin to reduce hypoglycemia in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul). 2015;30(1):84-91. doi: 10.3803/EnM.2015.30.1.84

18. Del Prato S, Patel S, Crowe S, von Eynatten M. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials. Nutr Metab Cardiovasc Dis. 2016;26(10):886-892. doi: 10.1016/j.numecd.2016.06.015

19. Sell H, Bluher M, Kloting N, et al. Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care. 2013;36(12):4083-4090. doi: 10.2337/dc13-0496

20. Maeda H, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract. 2012;95(1):e20-22. doi: 10.1016/j.diabres.2011.10.011

21. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2012;95(2):e27-28. doi: 10.1016/j.diabres.2011.08.016

22. Pratley RE, McCall T, Fleck PR, et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009;57(11):2011-2019. doi: 10.1111/j.1532-5415.2009.02484.x

23. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7):2402-2410. doi: 10.1210/jcem.85.7.6661

24. Chen H, Sullivan G, Quon MJ. Assessing the Predictive Accuracy of QUICKI as a Surrogate Index for Insulin Sensitivity Using a Calibration Model. Diabetes. 2005;54(7):1914-1925. doi: 10.2337/diabetes.54.7.1914

25. Kim-Dorner SJ, Deuster PA, Zeno SA, et al. Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance? Metabolism. 2010;59(2):299-304. doi: 10.1016/j.metabol.2009.07.027

26. Roytberg GE, Dorosh JV, Sharkhun OO, et al. New Metabolic Index Use Potentialities in Evaluation of Insulin Resistance in Clinical Practice. Rational Pharmacotherapy in Cardiology. 2014;10(3):264-274. doi: 10.20996/1819-6446-2014-10-3-264-274

27. Fang L, Li X. Level of serum phosphorus and adult type 2 diabetes mellitus. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2016;41(5):502-506. doi: 10.11817/j.issn.1672-7347.2016.05.009

28. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012;92(1):131-155. doi: 10.1152/physrev.00002.2011

29. Mirza MA, Alsio J, Hammarstedt A, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011;31(1):219-227. doi: 10.1161/ATVBAHA.110.214619

30. Mancini FR, Affret A, Dow C, et al. High dietary phosphorus intake is associated with an increased risk of type 2 diabetes in the large prospective E3N cohort study. Clin Nutr. 2018;37(5):1625-1630. doi: 10.1016/j.clnu.2017.07.025

31. Cederberg H, Stancakova A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58(5):1109-1117. doi: 10.1007/s00125-015-3528-5

32. Casula M, Mozzanica F, Scotti L, et al. Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27(5):396-406. doi: 10.1016/j.numecd.2017.03.001

33. Betteridge DJ, Carmena R. The diabetogenic action of statins – mechanisms and clinical implications. Nat Rev Endocrinol. 2016;12(2):99-110. doi: 10.1038/nrendo.2015.194

34. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373(9677):1765-1772. doi: 10.1016/s0140-6736(09)60697-8

35. Li Z, Li Y, Liu Y, et al. Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: A network meta-analysis. J Clin Hypertens (Greenwich). 2017;19(12):1348-1356. doi: 10.1111/jch.13108

36. Das UN. Renin-angiotensin-aldosterone system in insulin resistance and metabolic syndrome. J Transl Int Med. 2016;4(2):66-72. doi: 10.1515/jtim-2016-0022